oral PARP1-DNA selective trapper

1 mpk QD in PDX model, phase I/II, cancer

from literature starting point

Journal of Medicinal Chemistry


The AstraZeneca PARP1-DNA trapper, AZD5305, is a phase I candidate (NCT04644068) for cancer that is selective for PARP1 over PARP2 (>500x). Their study began by profiling the existing clinical and late-stage…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.